Sold as Ifex/Mesnex. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Ifosfamide; Mesna (sold as Ifex/Mesnex), first approved Aug 14, 1987, with 0 new uses approved and 0 published complete response letters.
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Ifosfamide Injection | Current | Jun 12, 2026 | Nov 3, 2026 |
| Phase II Study of QLC2519 in Pediatric Solid Tumor ParticipantsPediatric Malignant Solid Tumor, Febrile Neutropenia (FN) · Qilu Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Jul 24, 2026 |
| Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLDLBCL - Diffuse Large B Cell Lymphoma · The First Affiliated Hospital with Nanjing Medical University | Not applicable | Not yet recruiting | Feb 5, 2026 |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaFollicular Lymphoma · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 | Not yet recruiting | Sep 23, 2025 |
| Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate CancerProstatic Neoplasm · Yonsei University | — | Recruiting | Feb 1, 2024 |
| Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T TherapiesB-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Active, not recruiting | Jan 23, 2024 |
| Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell TumorsNon-Seminomatous Germ Cell Tumor · Gustave Roussy, Cancer Campus, Grand Paris | Not applicable | Recruiting | Jan 31, 2023 |
| A Study of N9 Chemotherapy in Children With NeuroblastomaNeuroblastoma, Pediatric Cancer · Memorial Sloan Kettering Cancer Center | Early phase 1 | Active, not recruiting | Jul 1, 2021 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)Pediatric Solid Tumor, Osteosarcoma · St. Jude Children's Research Hospital | Phase 1 | Recruiting | May 21, 2021 |
| Aug 14, 1987 | Ifex, Ifex/MesnexNDA 19763 · New molecular entity | Baxter Hlthcare | 16 | Marketed |
| Feb 26, 2002 | Ifosfamide/MesnaANDA 75874 | Teva Pharms USA | 6 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA